Stereotaxis is expected to report Q3 2026 revenue of $8.1 million and an EPS loss of $0.05, while its current price of $2.14 sits significantly below the $5.50 average analyst price target. The primary focus for investors is the commercial adoption and order backlog of the Genesis RMN System following its broader international rollout. Recent performance has been driven by the transition to this next-generation robotic platform and progress toward regulatory clearance for the MAGiC catheter.
Market participants are also looking for updates on the company's path to profitability and the impact of its collaborations in the electrophysiology space.